WHY O	1 Till	, ק נ									Sheet	1 of 2	
FORMETO-1446 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE 2710-4007 US1								1	SERIAL NO. 09/302,896				
INF	ORM	ATI	ON DISCLOSU	RE CITAT	TION								
		4	on Discisor	ill Citat	M. B. CHANCE			ELLOR and J. HUARD					
(Use several sheets if necessary)						April 30, 1999				GROUP ART UNIT 1643 / (36			
				U.S.	PATENT	DOCUI	MENTS						
EXAMINER INITIAL		DOCUMENT NUMBER		DATE		NAME		CLASS	SUBCLASS		FILING DATE IF APPROPRIATE		
R	1	5,:	594,032	1/14/97	Gonzalez-Cadav		id et al.	514	645				
			FOREIGN PATENT DOCUMENTS										
											TRANSLATION		
		D	OCUMENT NUMBER	DATE		COUNTRY		CLASS	SUBCLASS		YES	NO	
2	2	w	O 98/36055	20/8/98	PCT	PCT			_				
Se	3	w	O 96/18303	20/6/86	РСТ	РСТ			_				
æ	4	W	O 99/47163	23/9/99	PCT				_				
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Papers, Etc.)													
A		5	M. Reza Dana et al., "Interleukin-1 Receptor Antagonist Suppresses Langerhans Cell Activity and Promotes Ocular Immune Privilege", <u>Investigative Ophthalmology & Visual Science</u> , 1998, 39:70-77.										
Sa		6	G. Ferrari et al., "Muscle Regeneration by Bone Marrow-Derived Myogenic Progenitors", Science, 1998, 279:1528-1530.										
D		7	E. Barr and J. Leiden, "Systemic Delivery of Recombinant Proteins by Genetically Modified Myoblasts", Science, 1991, 254:1507-1509.										
Se		8	T. Katagiri et al., "Bone Morphogenetic Protein-2 Converts the Differentiation Pathway of C2C12 Myoblasts into the Osteoblast Lineage", J. Cell Biology, 1994, 127:1755-1766.										
8		9	T.A. Rando and H. Blau, "Primary Mouse Myoblast Purification, Characterization, and Transplantation for Cell-mediated Gene Therapy", J. Cell Biology, 1994, 125:1275-1287.										
e .			*								•		
EXAMINER DATE CONSIDERED 1/22/14							14						
-					- L						,		

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

B	, Mb		9							Sheet	2 of 2		
FORM PTO-1 TO THAT S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)						ATTY, DOCKET NO. 2710-4007 US	SERIAL NO. 09/302,896						
						APPLICANT M. B. CHANCELLOR and J. HUARD							
						FILING DATE April 30, 1999		GROUP ART UNIT 1643 1636					
				U.S.	PATENT I	OCUMENTS							
EXAMINER INITIAL		DX.	CUMENT NUMBER	DATE		NAME	CLASS	SUBCLASS		FILING DATE IF APPROPRIATE			
				FOREIG	N PATEN	T DOCUMENT	S						
		CUMENT NUMBER	DATE		COUNTRY	CLASS	SUBCLASS		TRANSLATION				
	 								-	YES	NO		
	1		THE DOCUM	EENPEC A					**				
	T	ı	THER DOCUM	LENIS (Inc	uaing Auth	or, Title, Date, I	ertinent P	apei	s, Elc.)				
R		10	Adenovirus Tr	ansfected wi	th Human I	s a Potential Trea nductible Nitric (applement:305 (Oxide Syn	thase	(iNOS)				
Q		11	J. Huard et al., "Myoblast Injection into the Bladder Wall: A Possible Method of Modulating Detrusor Contractility and Cell-Mediated Gene Therapy for Bladder Dysfunction", J. Urology, 1998, 159 (5) Supplement: 16 (Abstract 62).										
Q		12	J. Huard et al., "Nitric Oxide Synthase (NOS) Gene Therapy for Erectile Dysfunction; Comparison Between Plasmid, Adenovirus and Adenovirus Transduced Myoblast Vectors", J. Urology, 1998, 159:90 (Abstract 342).										
			·										
			-87										
						·							
EXAMINER			I.M.	SAL DA			ATE CONSIDERED 1/22/24						
EXAMINE: through cita applicant.	R: Li	nitial if not	if reference cons in conformance	idered, whet	ther or not o	citation is in conf clude copy of this	ormance v s form wit	vith i	MPEP 60 kt commu	9; Draw I	ine o		